PHK
UROV

Point72 Hong Kong’s Urovant Sciences Ltd. UROV Stock Holding History

Point72 Hong Kong’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-686
Closed -$5K – 1382
2018
Q4 		$5K Sell
686
-11,576
-94% -$105K ﹤0.01% 645
2018
Q3 		$147K Buy
+12,262
New +$145K 0.05% 270

Other funds holding UROV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Hong Kong's UROV Position: Q1 2019 in Review

Point72 Hong Kong sold out of Urovant Sciences Ltd. (UROV) in Q1 2019, closing a stake of 686 shares — an estimated $5K sold.

Point72 Hong Kong first reported a position in UROV in Q3 2018 and held it in 2 quarters. The position peaked at $147K in Q3 2018. 21 funds tracked by Wall St. Rank hold UROV as of Q1 2019.

  • Point72 Hong Kong reported no remaining Urovant Sciences Ltd. position as of Q1 2019 after selling out during the quarter.
  • Point72 Hong Kong sold 686 Urovant Sciences Ltd. shares in Q1 2019, an estimated $5K.
  • Point72 Hong Kong first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 2 quarters.
  • Point72 Hong Kong's Urovant Sciences Ltd. position peaked at $147K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2019.

Based on Point72 Hong Kong's 13F filing for Q1 2019, filed 15 May 2019.